Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy. The Danish ...
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent mandate. Hims pushed back against the accusation. Reading time 3 minutes ...
Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth ...
Earnings date set: Hims & Hers will release Q1 2026 results on May 11, with consensus revenue near $616M and EPS at $0.13.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results